EA202190603A1 - Полипептиды анти-her2 и способы их применения - Google Patents

Полипептиды анти-her2 и способы их применения

Info

Publication number
EA202190603A1
EA202190603A1 EA202190603A EA202190603A EA202190603A1 EA 202190603 A1 EA202190603 A1 EA 202190603A1 EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A1 EA202190603 A1 EA 202190603A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her2
antibody
methods
bbb
application
Prior art date
Application number
EA202190603A
Other languages
English (en)
Russian (ru)
Inventor
Марк С. Деннис
Ванда Кван
Джозеф В. Льюкок
Джонатан Соколоски
Джой Ю Дзукеро
Original Assignee
Денали Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Денали Терапьютикс Инк. filed Critical Денали Терапьютикс Инк.
Publication of EA202190603A1 publication Critical patent/EA202190603A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA202190603A 2018-08-22 2019-08-22 Полипептиды анти-her2 и способы их применения EA202190603A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
PCT/US2019/047728 WO2020041604A1 (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202190603A1 true EA202190603A1 (ru) 2021-07-14

Family

ID=67989062

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190603A EA202190603A1 (ru) 2018-08-22 2019-08-22 Полипептиды анти-her2 и способы их применения

Country Status (15)

Country Link
US (1) US20220002436A1 (https=)
EP (1) EP3840781A1 (https=)
JP (2) JP2021534220A (https=)
KR (1) KR20210074279A (https=)
CN (1) CN113286610A (https=)
AR (1) AR115998A1 (https=)
AU (2) AU2019326545A1 (https=)
BR (1) BR112021002953A2 (https=)
CA (1) CA3141815A1 (https=)
EA (1) EA202190603A1 (https=)
IL (2) IL326298A (https=)
MX (1) MX2021001976A (https=)
SG (1) SG11202101436SA (https=)
TW (1) TW202017947A (https=)
WO (1) WO2020041604A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
AU2021224200A1 (en) * 2020-02-19 2022-09-08 Denali Therapeutics Inc. Engineered anti-HER2 bispecific proteins
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2023038803A2 (en) * 2021-08-25 2023-03-16 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
EP4631975A1 (en) * 2022-12-08 2025-10-15 Adel Inc. Fusion comprising anti-tau antibody and peptide and use thereof
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699826B1 (en) * 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
HUE045144T2 (hu) * 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CN107531788B (zh) * 2015-06-24 2022-06-21 豪夫迈·罗氏有限公司 对her2和血脑屏障受体特异性的三特异性抗体及使用方法
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
CN110506055A (zh) * 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
EP3665194A4 (en) * 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS

Also Published As

Publication number Publication date
CN113286610A (zh) 2021-08-20
IL280922B1 (en) 2026-03-01
AR115998A1 (es) 2021-03-25
WO2020041604A1 (en) 2020-02-27
BR112021002953A2 (pt) 2021-05-11
US20220002436A1 (en) 2022-01-06
JP2024150674A (ja) 2024-10-23
IL280922A (en) 2021-04-29
CA3141815A1 (en) 2020-02-27
EP3840781A1 (en) 2021-06-30
KR20210074279A (ko) 2021-06-21
AU2026200081A1 (en) 2026-01-29
JP7818042B2 (ja) 2026-02-19
MX2021001976A (es) 2021-06-08
AU2019326545A1 (en) 2021-03-11
SG11202101436SA (en) 2021-03-30
TW202017947A (zh) 2020-05-16
IL326298A (en) 2026-04-01
JP2021534220A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
EA202190603A1 (ru) Полипептиды анти-her2 и способы их применения
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
SA520420748B1 (ar) أجسام مضادة للمركب الترابطي شبيه دلتا 3 /مجموعة من التمايز 3 ثنائية الخاصية
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
MX2023007520A (es) Aglutinantes de albumina de suero mejorados.
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
MX2025010630A (es) Aglutinantes de albumina serica mejorados
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
ATE509032T1 (de) Chimerizierte gm-csf antikörper
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
EA201992467A1 (ru) ГЕТЕРОДИМЕРИЗУЮЩИЕСЯ ДОМЕНЫ Ig
MX2023011712A (es) Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
BR112022010824A2 (pt) Anticorpo bifuncional contra pd-l1 e tgf¿
EA202193222A1 (ru) Определение характеристик домен-специфических зарядовых вариантов антител
JOP20230223A1 (ar) بولي ببتيد ربط gucy2c واستخداماته